Evidence map›Paper›PMID 27889809›Full record

Trial reportDiabetologia2017

Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study.

Megan L Gow, Louise A Baur, Nathan A Johnson, Chris T Cowell, Sarah P Garnett

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03459573 (Fit-One), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03459573 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Fit-One: A Randomized Waitlist Controlled Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes

TypeinterventionalSponsorChandra Osborn, PhD, MPHRan2018 to 2019Enrolled500ConditionsDiabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, PreDiabetesArmsOne Drop, Experts On Track, One Drop, Experts On Call, One Drop
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Treatment of adolescent obesity.Nature reviews. Endocrinology · 2018
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Megan L GowDiscipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia. megan.gow@health.nsw.gov.au.
Louise A BaurDiscipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia.
Nathan A JohnsonFaculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.
Chris T CowellInstitute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Corner of Hawkesbury Road and Hainsworth Street, Locked Bag 4001, Westmead, NSW, 2145, Australia.
Sarah P GarnettDiscipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia.
University of Sydney · AUChildren's Hospital at Westmead · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisThe aim of the study was to investigate whether a very-low-energy diet (VLED) is a feasible and acceptable treatment option for type 2 diabetes in children and adolescents, and whether adherence can lead to rapid weight loss, reversal of type 2 diabetes and reduced liver fat as seen in adult studies.

methodsEight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks. HbA

resultsAdherers (n = 5) and non-adherers (n = 3) had median weight loss of 7.5% and 0.5%, respectively, at 8 weeks. Overall, HbA CONCLUSIONS/

interpretationA VLED appears to be a feasible treatment option for some youth with type 2 diabetes on metformin therapy. Youth who agree to participate and adhere to a VLED achieve rapid weight loss, dramatic reductions in liver fat and reversal of type 2 diabetes. This highlights the capacity of a VLED to be used as a first-line treatment option in newly diagnosed youth. A larger trial with a control group and longer follow-up will be required to encourage a change in standard treatment.

trial registrationAustralian New Zealand Clinical Trial Registration Number (ACTRN) ACTRN12616000375459 ( www.ANZCTR.org.au/ACTRN12616000375459.aspx ).

Indexed as

AdolescentBlood GlucoseCaloric RestrictionChildDiabetes Mellitus, Type 2Diet, ReducingFastingGlucose Tolerance TestGlycated HemoglobinHumansInsulinLiverMetforminObesityPancreasPilot ProjectsBlood GlucoseGlycated HemoglobinInsulinMetforminAdolescentsChildrenLiver fatType 2 diabetesVery-low-energy dietYouth

Identifiers

PMID27889809
OpenAlexW2555909154

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.